今日盘中,巨子生物股价大涨5.03%,引起市场广泛关注。
消息面上,券商机构看好公司未来表现。摩根士丹利最新研报预期巨子生物未来15天股价有约70%至80%上升空间,目标价为65港元,给予"增持"评级。该行预计公司2024及2025财年盈利分别增长37%和23%,高于同行业公司,即将公布的全年业绩或更为强劲。
同时公司旗下两大品牌可复美和可丽金在去年"双11"大促期间再创佳绩,线上全渠道GMV分别同比增长80%+和150%+,支撑公司达成全年盈利目标。巨子生物作为全球重组胶原蛋白领导者,主要研发产销专业皮肤护理产品,属于高增长赛道,具备增长确定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
No relevant data is available
If the download button clicks without skipping, click on the top right menu and select "Open in Browser."